Application to terminate the implementation of the project titled: Development and clinical development of a first-in-class small-molecule drug candidate for the treatment of colorectal cancer

Current report no. 53/2025

Drafting date: 14.11.2025

Subject: Application to terminate the implementation of the project titled: “Development and clinical development of a first-in-class small-molecule drug candidate for the treatment of colorectal cancer based on the stimulation of cells of the immune system to increased anti-cancer activity through induced protein degradation.”

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A., based in Wrocław (the “Company”), informs that on 14.11.2025, Company has submitted to the Medical Research Agency an application to terminate the implementation of the project titled: “Development and clinical development of a first-in-class small-molecule drug candidate for the treatment of colorectal cancer based on the stimulation of cells of the immune system to increased anti-cancer activity through induced protein degradation” (“Project”).

Project is at an early stage of development and in the Company’s assessment, due to the occurrence of significant scientific risk, the continued implementation of the Project does not promise the achievement of the intended results and objectives and is therefore not justified in terms of efficiency and cost-effectiveness.